Systemic Sclerosis

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis
Christopher P Denton, Voon H Ong, Shiwen Xu, Haiyin Chen-Harris, Zora Modrusan, Robert Lafyatis, Dinesh Khanna, Angelika Jahreis, Jeffrey Siegel, Thierry Sornasse

Annals of the Rheumatic Diseases Sep 2018, 77 (9) 1362-1371; DOI: 10.1136/annrheumdis-2018-213031
Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model
Wanlong Wu, Suzana Jordan, Mike Oliver Becker, Rucsandra Dobrota, Britta Maurer, Håvard Fretheim, Shuang Ye, Elise Siegert, Yannick Allanore, Anna-Maria Hoffmann-Vold, Oliver Distler

Annals of the Rheumatic Diseases Sep 2018, 77 (9) 1326-1332; DOI: 10.1136/annrheumdis-2018-213201
Tracking digital ulcers in systemic sclerosis: a feasibility study assessing lesion area in patient-recorded smartphone photographs
Graham Dinsdale, Tonia L Moore, Joanne B Manning, Andrea K Murray, Ross Atkinson, Karen Ousey, Mark R Dickinson, Christopher Taylor, Ariane L Herrick

Annals of the Rheumatic Diseases Sep 2018, 77 (9) 1382-1384; DOI: 10.1136/annrheumdis-2017-212829
Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis
Stefano Soldano, Amelia Chiara Trombetta, Paola Contini, Veronica Tomatis, Barbara Ruaro, Renata Brizzolara, Paola Montagna, Alberto Sulli, Sabrina Paolino, Carmen Pizzorni, Vanessa Smith, Maurizio Cutolo

Annals of the Rheumatic Diseases Jul 2018, annrheumdis-2018-213648; DOI: 10.1136/annrheumdis-2018-213648
Response to: ‘Can we further SPARkle the SPAR model?’ by Kavadichanda et al
Wanlong Wu, Suzana Jordan, Oliver Distler

Annals of the Rheumatic Diseases Jul 2018, annrheumdis-2018-213962; DOI: 10.1136/annrheumdis-2018-213962
Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis
Eloisa Romano, Mirko Manetti, Irene Rosa, Bianca Saveria Fioretto, Lidia Ibba-Manneschi, Marco Matucci-Cerinic, Serena Guiducci

Annals of the Rheumatic Diseases Jul 2018, annrheumdis-2018-213239; DOI: 10.1136/annrheumdis-2018-213239
Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts
Ye He, Pei-Suen Tsou, Dinesh Khanna, Amr H Sawalha

Annals of the Rheumatic Diseases Aug 2018, 77 (8) 1208-1218; DOI: 10.1136/annrheumdis-2018-213022
Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer
Takeru Igusa, Laura K Hummers, Kala Visvanathan, Carrie Richardson, Fredrick M Wigley, Livia Casciola-Rosen, Antony Rosen, Ami A Shah

Annals of the Rheumatic Diseases Aug 2018, 77 (8) 1179-1186; DOI: 10.1136/annrheumdis-2018-212999
Variation in antinuclear antibody detection: need for clear expectations and additional studies
Michael Mahler, Carolina Auza

Annals of the Rheumatic Diseases Jun 2018, annrheumdis-2018-213888; DOI: 10.1136/annrheumdis-2018-213888
Can we further SPARkle the SPAR model?
Chengappa G Kavadichanda, Vir Singh Negi

Annals of the Rheumatic Diseases Jun 2018, annrheumdis-2018-213954; DOI: 10.1136/annrheumdis-2018-213954

Main menu

Systemic Sclerosis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Systemic Sclerosis

Pages